BkofA Merrill Lynch

Form 38.5 (b) - AbbVie

RNS Number : 3503C
Bank of America Merrill Lynch
07 February 2020
 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader

BofA Securities, Inc.

Company dealt in

AbbVie Inc

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - US00287Y1091

Date of dealing

06/02/2020

 

2.

INTERESTS AND SHORT POSITIONS

(a)

Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)

Class of relevant security: Common

US00287Y1091


Long

Short

Number

%

Number

%

(1)

Relevant securities

132,897

0.009%

2,628,292

0.178 %

(2)

Derivatives (other than options):

1,927,997

0.13%

155,157

0.01%

(3)

Options and agreements to purchase/sell:

7,400

0.001%

7,500

0.001%

Total

2,068,294

0.140%

2,790,949

0.189%

 

(b)

Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)

Class of relevant security:



Long

Short

Number

%

Number

%

(1)

Relevant securities

0

0%

0

0%

(2)

Derivatives (other than options):

0

0%

0

0%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

3.

DEALINGS (Note 3)

(a)

Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

          87

86.45 USD

Purchase

        231

86.52 USD

Purchase

          65

86.54 USD

Purchase

        187

86.6 USD

Purchase

        173

86.66 USD

Purchase

        259

86.74 USD

Purchase

          20

86.88 USD

Purchase

            2

86.9 USD

Purchase

        273

86.95 USD

Purchase

        347

86.96 USD

Purchase

          87

86.965 USD

Purchase

     1,150

86.97 USD

Purchase

        176

86.98 USD

Purchase

        513

86.99 USD

Purchase

          87

87 USD

Purchase

     1,207

87.02 USD

Purchase

        507

87.03 USD

Purchase

          87

87.04 USD

Purchase

        400

87.05 USD

Purchase

        100

87.07 USD

Purchase

        200

87.075 USD

Purchase

        101

87.08 USD

Purchase

        100

87.09 USD

Purchase

        447

87.1 USD

Purchase

            1

87.105 USD

Purchase

     1,280

87.11 USD

Purchase

        681

87.12 USD

Purchase

        100

87.13 USD

Purchase

     1,847

87.18 USD

Purchase

        190

87.19 USD

Purchase

        340

87.24 USD

Purchase

     8,856

87.604 USD

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale

          14

86.3 USD

Sale

        112

86.31 USD

Sale

          36

86.32 USD

Sale

        100

86.34 USD

Sale

        100

86.35 USD

Sale

          29

86.36 USD

Sale

        100

86.37 USD

Sale

          18

86.39 USD

Sale

          15

86.425 USD

Sale

        211

86.44 USD

Sale

          13

86.45 USD

Sale

          17

86.46 USD

Sale

          15

86.47 USD

Sale

          30

86.49 USD

Sale

          27

86.5 USD

Sale

        296

86.52 USD

Sale

        118

86.53 USD

Sale

          24

86.54 USD

Sale

          25

86.55 USD

Sale

            7

86.56 USD

Sale

          13

86.57 USD

Sale

            6

86.575 USD

Sale

            5

86.58 USD

Sale

            6

86.59 USD

Sale

          59

86.62 USD

Sale

        100

86.63 USD

Sale

        168

86.64 USD

Sale

          16

86.65 USD

Sale

          17

86.66 USD

Sale

        100

86.68 USD

Sale

        270

86.69 USD

Sale

          12

86.7 USD

Sale

        623

86.71 USD

Sale

            7

86.73 USD

Sale

        160

86.74 USD

Sale

        145

86.75 USD

Sale

        223

86.76 USD

Sale

        382

86.77 USD

Sale

        400

86.775 USD

Sale

     3,820

86.78 USD

Sale

        300

86.785 USD

Sale

     1,720

86.79 USD

Sale

     1,855

86.8 USD

Sale

        335

86.81 USD

Sale

     2,200

86.815 USD

Sale

        195

86.82 USD

Sale

        295

86.83 USD

Sale

        886

86.84 USD

Sale

        453

86.85 USD

Sale

        352

86.86 USD

Sale

        189

86.87 USD

Sale

        817

86.88 USD

Sale

        178

86.89 USD

Sale

        277

86.9 USD

Sale

        192

86.91 USD

Sale

        135

86.92 USD

Sale

        176

86.93 USD

Sale

        125

86.94 USD

Sale

        100

86.95 USD

Sale

        227

86.96 USD

Sale

        215

86.97 USD

Sale

          30

86.98 USD

Sale

        117

87 USD

Sale

          30

87.02 USD

Sale

          30

87.03 USD

Sale

        585

87.032 USD

Sale

          85

87.04 USD

Sale

          27

87.06 USD

Sale

            3

87.15 USD

Sale

            4

87.17 USD

Sale

    87,611

87.18 USD

Sale

            4

87.19 USD

Sale

            3

87.21 USD

Sale

            3

87.25 USD

Sale

          86

87.28 USD

Sale

          10

87.33 USD

Sale

            7

87.34 USD

Sale

        292

87.51 USD

Sale

        125

87.52 USD

Sale

        200

87.525 USD

Sale

        475

87.53 USD

Sale

        200

87.54 USD

Sale

        100

87.55 USD

Sale

        576

87.56 USD

Sale

        100

87.565 USD

Sale

        906

87.57 USD

Sale

        616

87.58 USD

Sale

        300

87.59 USD

Sale

        100

87.595 USD

Sale

        100

87.6 USD

Sale

        100

87.605 USD

Sale

        800

87.61 USD

Sale

        301

87.62 USD

Sale

        100

87.625 USD

Sale

        200

87.63 USD

Sale

     1,053

87.65 USD

Sale

        800

87.655 USD

Sale

        300

87.66 USD

Sale

     1,100

87.67 USD

Sale

        186

87.69 USD

Sale

          87

87.76 USD

Sale

          87

87.82 USD

Sale

          86

87.83 USD

Sale

          86

87.88 USD

Sale

        100

87.89 USD

Sale

        100

87.9 USD

Sale

     1,700

87.18 USD

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 5)

Number of relevant securities
(Note 6)

Price per unit
(Note 4)

Swaps

Increasing a Long Position

87,608

87.18 USD

Swaps

Reducing a Short Position

376

87.022 USD

Swaps

Reducing a Short Position

188

87.022 USD

Swaps

Reducing a Short Position

21

87.109 USD

Swaps

Reducing a Short Position

1,200

86.814 USD

Swaps

Closing a Short Position

300

86.814 USD

Swaps

Opening a Long Position

700

86.814 USD

Swaps

Reducing a Long Position

509

87.167 USD

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 4)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 4)

N/A

N/A

N/A

 

(d)

Other dealings (including transactions in respect of new securities) (Note 3)

Nature or transaction
(Note 7)

Details

Price per unit
(if applicable)
(Note 4)




Borrow

Borrow of 285,400 shares

N/A

Borrow

Borrow of 89,600 shares

N/A

Borrow

Borrow of 78,920 shares

N/A

 

4.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

 

Is a Supplemental Form 38.5(b) attached? (Note 8)

Yes

 

Date of disclosure

07/02/2020

Contact name

Tolu Tade

Telephone number

+44207 996 3410

Name of offeree/offeror with which connected

AbbVie Inc

Nature of connection (Note 9)

Advisor to - AbbVie Inc

 

 

 

 

 

 

 

 

SUPPLEMENTAL FORM 38.5(b)


DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

Product name,
e.g. call option

Written or
purchased

Number of securities to which the option or derivative relates

Exercise price
(Note 2)

Type, e.g.
American,
European etc

Expiry date

Call Option

 Written

        7,500

105 USD

 American

15/01/2021

 Call Option

 Purchased

        7,400

 85 USD

 American

15/01/2021

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEUBRARRKUURAR